The compounds presented are investigational or are being investigated for uses that have not been approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), or other health authorities. This information is presented only for purposes of providing a general overview of clinical trials and should not be construed as a recommendation for use of any product for unapproved uses.

This website is intended for healthcare professionals only

Slide banner

WRN Inhibitor (BAY 3772392)

See how this compound is being investigated across Bayer’s oncology pipeline

Explore the tumor types, areas of research, and clinical trials associated with this investigational compound.

image_sqrt

Compound Overview

WRN inhibitor (BAY 3772392) is a selective inhibitor of Werner syndrome protein (WRN), a DNA repair enzyme involved in maintaining genome stability during DNA replication. It demonstrates synthetic lethality through covalent inhibition of WRN, triggering double-stranded DNA breaks, nuclear swelling, and cell death.1

This targeted approach is being investigated for the treatment of cancers characterized by high microsatellite instability biology, including colorectal cancer.1

Tumor Types

Gastrointestinal cancer (colorectal)
Solid tumors

Area of Research

DNA damage response

Clinical Trial

Tumor Type(s)

Phase

Status

Description

NCT Number

Solid Tumors, Gastrointestinal Cancer (Colorectal)

I

Now Enrolling

A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors

NCT06004245

Gastrointestinal Cancer (Colorectal)

II

Now Enrolling

A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

NCT07811193 

Bayer’s Oncology Pipeline Brochure

Explore a comprehensive overview of Bayer's oncology pipeline, including investigational compounds, clinical trials, and areas of research.

Download BrochurePDF (1.45 MB)

The ongoing clinical trials listed on this website represent a comprehensive overview of Bayer's clinical pipeline in Oncology, including Bayer-sponsored research and collaborative research with academic centers, cooperative groups, and other global institutions.